A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection

Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY

The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing. The study includes four arms based on biopsy location and biopsy modality/tool: 1. Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx) 2. Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA) 3. Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA) 4. Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Healthy Volunteers: f
View:

• The patient or legal guardian is willing and able to understand, sign and date the Ethics committee approved study specific Informed Consent Form.

• The patient is 22 years of age or older.

• The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.

• The patient can tolerate the clinical procedure as indicated.

Locations
United States
California
UC San Diego
RECRUITING
San Diego
Florida
Mayo Clinic Jacksonville
NOT_YET_RECRUITING
Jacksonville
Michigan
Corewell Health
RECRUITING
Grand Rapids
North Carolina
UNC Medical Center
RECRUITING
Chapel Hill
New York
Memorial Sloan Kettering Cancer Center
SUSPENDED
New York
Montefiore Medical Center
RECRUITING
The Bronx
Texas
MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING
Houston
Time Frame
Start Date: 2023-12-21
Estimated Completion Date: 2026-05
Participants
Target number of participants: 900
Treatments
ON-SITE Patients
Participants must fulfill all of the following criteria in order to be eligible for the study:~1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee-approved study specific Informed Consent Form.~2. The patient is 22 years of age or older.~3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral-TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.~4. The patient can tolerate the clinical procedure as indicated.
Related Therapeutic Areas
Sponsors
Collaborators: Mayo Clinic, University of California, San Diego, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Corewell Health, Montefiore Medical Center-Moses-Weiler, University of North Carolina, Chapel Hill
Leads: Invenio Imaging Inc.

This content was sourced from clinicaltrials.gov